CLINICAL TRIALS PROFILE FOR APREMILAST
✉ Email this page to a colleague
All Clinical Trials for APREMILAST
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00456092 ↗ | Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis | Completed | Amgen | Phase 2 | 2007-03-05 | This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis. |
NCT00456092 ↗ | Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis | Completed | Celgene Corporation | Phase 2 | 2007-03-05 | This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis. |
NCT00521339 ↗ | Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis | Completed | Amgen | Phase 2 | 2007-08-01 | The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis. |
NCT00521339 ↗ | Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis | Completed | Celgene Corporation | Phase 2 | 2007-08-01 | The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for APREMILAST
Condition Name
Clinical Trial Locations for APREMILAST
Trials by Country
Clinical Trial Progress for APREMILAST
Clinical Trial Phase
Clinical Trial Sponsors for APREMILAST
Sponsor Name